Japan Clears First iPS Cell Therapies for Sale, Launching a High-Stakes Test of Regenerative Medicine

On March 6, in a conference room at Japan’s Ministry of Health, Labour and Welfare in Tokyo, Health Minister Kenichiro Ueno signed off on a decision that shifts a long-running scientific bet into everyday medicine.

With two approval notices, the ministry granted conditional, time-limited authorization for the world’s first therapies made from induced pluripotent stem cells, or iPS cells—lab-grown cells reprogrammed from adult tissue and coaxed into becoming specific types of human cells.

The approvals cover Amchepry, a cell transplant for Parkinson’s disease, and ReHeart, a heart muscle cell sheet for severe heart failure. Both are based on donor-derived iPS cells and will be eligible for coverage under Japan’s public health insurance once prices are set.

A global first—built on small early trials

The move makes Japan the first country to clear iPS cell therapies for sale, not just experimental use. It also tests how far regulators are willing to go in trading traditional large trials for speed, with the Parkinson’s product supported by data from seven patients and the heart therapy from eight.

Amchepry (generic name raguneprocel) is an allogeneic iPS-derived dopaminergic neural progenitor cell therapy for people with Parkinson’s disease whose motor symptoms are not adequately controlled by existing drugs, including levodopa. The product is being developed by Sumitomo Pharma Co. with cell therapy company RACTHERA Inc.

In the procedure, neurosurgeons perform stereotactic surgery to inject Amchepry directly into the putamen, a part of the brain’s basal ganglia where dopamine-producing neurons degenerate in Parkinson’s. The transplanted cells are intended to mature into dopamine neurons and restore some of the lost signaling.

ReHeart is an iPS-derived cardiomyocyte sheet therapy created by Cuorips Inc., a Tokyo-based start-up spun out of Osaka University. Surgeons apply thin sheets of heart muscle cells—each sheet containing roughly 100 million cells—to the surface of a damaged heart. The target patients are people with severe heart failure caused by ischemic cardiomyopathy who have exhausted standard drug and device treatments and often face long waits or ineligibility for heart transplants.

In both cases, the cells are produced from donor iPS cell lines under manufacturing standards for medical products. The goal is to offer “off-the-shelf” regenerative treatments that can be supplied to hospitals when needed, rather than bespoke therapies made from each patient’s own cells.

Japan’s fast-track framework for regenerative products

The approvals rest on Japan’s special framework for regenerative medicine. In 2014, revisions to the Pharmaceuticals and Medical Devices Act created a distinct category of “regenerative medical products” and a pathway for “conditional and time-limited” marketing authorization.

Under that system, the health ministry can grant up to seven years of conditional approval if early data suggest a product is likely effective and its potential benefits outweigh the known risks, even if conventional large-scale trials are not yet complete.

Amchepry and ReHeart are the first iPS-based products to use this route. They follow a recommendation issued Feb. 19 by an expert panel of the Pharmaceutical Affairs and Food Sanitation Council, which reviewed the data and advised the minister to grant conditional approval.

What the evidence shows—and what it doesn’t

The underlying evidence is modest by traditional drug standards.

Amchepry: seven patients

For Amchepry, investigators at Kyoto University Hospital led by neurosurgeon Jun Takahashi ran an open-label Phase 1/2 trial in seven patients with advanced Parkinson’s disease, aged 50 to 69. Patients received cell transplants at one of two dose levels and were followed for safety and changes in motor function.

Reports from the study describe improvements in motor scores, particularly during periods when patients’ standard medications were active. In one analysis, average motor scores during “on” periods improved by about a third compared with baseline. No tumors or serious adverse events directly attributed to the grafts were observed in the follow-up period that has been made public.

ReHeart: eight patients

ReHeart’s approval is based on an investigator-initiated trial in eight patients with severe ischemic cardiomyopathy treated at four Japanese hospitals, including Osaka University Hospital, between 2020 and 2023. Each patient typically received three cardiomyocyte sheets placed over scarred regions of heart muscle.

According to summaries released by the research team and government agencies, all eight patients showed improvements in symptoms or exercise capacity over a year of follow-up, and no cases of tumor formation were reported. As with the Parkinson’s trial, the study was small and designed primarily to assess safety and feasibility.

Neither product has been tested in a randomized, controlled Phase 3 trial. That has prompted some scientists and ethicists to question whether regulators have enough information to justify broad clinical use, particularly given theoretical risks that iPS-derived cells could form tumors or trigger immune reactions years after transplantation.

Conditions attached: seven years, plus post-marketing targets

Officials emphasize that the approvals are time-limited and come with strict conditions. The formal notices from the health ministry set a seven-year approval period for both Amchepry and ReHeart. During that time, the companies must conduct post-marketing studies and file for full approval based on the new data.

For Amchepry, the ministry has set a target of 35 Parkinson’s patients to receive the therapy under these studies. ReHeart is expected to be used in about 75 patients with severe ischemic cardiomyopathy during the conditional approval period. If confirmatory data fail to show sufficient benefit or reveal unacceptable risks, the approvals can be withdrawn.

A milestone for iPS science—and a pricing challenge

Announcing the decision, Ueno framed it as a milestone for Japanese science.

“I am very pleased that a therapeutic product from Japan based on Professor Yamanaka’s iPS cells has been put into practice for the first time in the world,” the minister said, adding that he hoped the therapies would “help patients not only in Japan but all over the world.”

Shinya Yamanaka, the Kyoto University researcher whose lab first reported mouse iPS cells in 2006 and human iPS cells in 2007, called the approvals a significant step.

“We are very pleased to have taken a major step toward social application on the 20th anniversary of the announcement of mouse iPS cells,” Yamanaka said in comments released through his institute.

Japan has poured public funds into iPS research since those early papers. The Center for iPS Cell Research and Application at Kyoto University and its affiliated CiRA Foundation have built clinical-grade cell stocks for use by companies and academic groups. The Japan Agency for Medical Research and Development has backed programs translating iPS technology into therapies, including the heart muscle sheets now commercialized as ReHeart.

The approvals now test whether that investment can translate into sustainable medical practice. Early estimates from analysts suggest the price of a single ReHeart procedure could exceed 10 million yen (more than $60,000), reflecting complex manufacturing and surgery. Amchepry is also expected to carry a high price, though official reimbursement levels will be set later in the year through Japan’s national health insurance system.

The government has recently debated how to set prices for conditionally approved regenerative products, with some industry groups warning that deep price cuts could discourage companies from pursuing high-risk cell therapies. At the same time, health officials face pressure to contain spending as more expensive biologics and gene therapies reach the market.

Why the world is watching

Global regulators and companies are watching closely. Japan’s willingness to approve iPS therapies on the basis of small, early-stage studies may influence discussions at agencies such as the U.S. Food and Drug Administration and the European Medicines Agency over how to regulate complex regenerative products. It also gives Japanese firms like Sumitomo Pharma and Cuorips a first-mover advantage as they seek partners and potential pathways to approvals in other markets.

For now, access will be limited to selected Japanese hospitals with the expertise to perform the delicate neurosurgical and cardiac procedures. Patients abroad are unlikely to receive the therapies unless they travel to Japan or enroll in future international trials.

Over the seven-year life of the conditional approvals, dozens of people with Parkinson’s disease and severe heart failure in Japan will undergo operations that were unimaginable when iPS cells were first described two decades ago. Their outcomes will help determine not just whether Amchepry and ReHeart win full approval, but how quickly reprogrammed cells move from national showcase to routine part of medical care.